Auven Therapeutics

About The Fund

Auven Therapeutics, also known as Fannin Innovation Studio, is an unconventional developer focused on creating vital products within the biomedical sector. They are situated at 3900 Essex Lane, Suite 575, Houston, Texas, 77027, United States. Auven Therapeutics primarily in-licenses promising, early-stage therapeutic and medical device technologies from leading academic investigators, particularly concentrating on the rich resources of the Texas Medical Center, and nationally. They lead the development of these in-licensed assets through preclinical work and engineering phases, progressing up to early clinical trials. With a profound commitment to addressing vital unmet medical needs, their mission is to develop early-stage pharmaceutical and medical device assets. They support the entrepreneurship ecosystem in life sciences both locally and nationally, helping to catalyze its growth and sustainability. Auven Therapeutics has a robust pipeline across various programs and boasts accomplishments like raising over $242 million through grant and investor funding, and training over 300 interns and fellows. Their unique value comes from their partnership approach with academic researchers, fostering innovation and aiming to transform patient care in the future. As a startup studio with expertise in equity investments, their specialties include expansion, later stage development, MBO/LBO, acquisition, recapitalization, and corporate divestiture. Additionally, they run an innovative internship program that equips new talent with real-world product development experience, which is highly regarded in the Houston biomedical commercialization ecosystem. Recognized for their strong relationships with institutions like Baylor College of Medicine and MD Anderson Cancer Center, Auven Therapeutics is a key player in advancing research from bench to bedside by developing and de-risking technologies efficiently and effectively.